Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
New Microbiol ; 37(3): 355-62, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25180850

RESUMO

We compared the in vivo efficacy of single large dose of caspofungin to that of daily smaller caspofungin doses (with same cumulative doses) against C. albicans (echinocandin susceptible and resistant isolates) and the â€Å“psilosisâ€? group in a neutropenic murine model. Seven treatment groups were formed for C. orthopsilosis, C. metapsilosis and C. albicans (no treatment, 1, 2 and 3 mg/kg caspofungin daily for five days; single 5, 10 and 15 mg/kg caspofungin doses). For C. parapsilosis there were five treatment groups (no treatment, 3 and 4 mg/kg caspofungin daily for five days; single 15 and 20 mg/kg caspofungin). Tissue burdens of C. orthopsilosis and C. parapsilosis were significantly decreased by daily 3 mg/kg and 10 or 15 mg/kg single caspofungin doses (P<0.05-0.01) and daily 4 mg/kg and by single 15 and 20 mg/kg caspofungin doses (P<0.05-0.01), respectively. Against C. metapsilosis all treatment arms except the daily 1 mg/kg were effective (P<0.05-<0.001). Against C. albicans all treatment doses were effective. Neither daily 16 mg/kg nor single 80 mg/kg were effective against the resistant C. albicans strain. Higher doses and less frequent administration of caspofungin were comparable or sometimes superior to the lower, daily-dose regimen against the â€Å“psilosisâ€? group supporting further studies with this therapeutic strategy.


Assuntos
Antifúngicos/administração & dosagem , Candida/efeitos dos fármacos , Candidíase/tratamento farmacológico , Equinocandinas/administração & dosagem , Neutropenia/tratamento farmacológico , Animais , Candida/classificação , Candida/isolamento & purificação , Candidíase/microbiologia , Caspofungina , Modelos Animais de Doenças , Feminino , Humanos , Lipopeptídeos , Camundongos , Camundongos Endogâmicos BALB C , Neutropenia/microbiologia
2.
Mycopathologia ; 178(3-4): 197-206, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25118874

RESUMO

It was previously demonstrated that brief (≤1 h) exposures to echinocandins are as effective to kill Candida albicans cells as continuous 24-h exposure. However, killing rates after continuous and short (1 h) echinocandin exposures to C. albicans have not yet been evaluated in RPMI-1640 with and without 50 % serum. We evaluated four echinocandin susceptible C. albicans bloodstream isolates, ATCC 10231 type strain and an echinocandin-resistant isolate (DPL20, FKS F645P). Caspofungin MICs, time-kill and postantifungal effect (PAFE) tests were performed in RPMI-1640 with and without 50 % serum. Killing rates (k values) in time-kill and PAFE experiments were determined for each strain and concentration. In time-kill experiments, colony count decreases were isolate- and concentration-dependent at 0.25, 1, 4, 8, 16 and 32 mg/L in RPMI-1640, but concentration-independent at 1, 4, 8, 16 and 32 mg/L in 50 % serum. One-hour caspofungin exposure at 4, 16 and 32 mg/L resulted in CFU decreases comparable with the results obtained in time-kill experiments in RPMI-1640, but 50 % serum at 4, 16 and 32 mg/L allowed growth of all isolates (k values were negative) (P < 0.05-0.001). PAFE in 50 % serum decreased markedly at 4, 16 and 32 mg/L. Killing rates remained high and concentration-independent in 50 % serum in case of continuous but not in case of brief caspofungin exposure. As only a short growth inhibition without killing was observed in 50 % serum, clinical relevance of caspofungin PAFE in vivo is questionable.


Assuntos
Antifúngicos/farmacologia , Candida albicans/efeitos dos fármacos , Equinocandinas/farmacologia , Viabilidade Microbiana/efeitos dos fármacos , Soro/metabolismo , Candida albicans/crescimento & desenvolvimento , Candida albicans/isolamento & purificação , Candidemia/microbiologia , Caspofungina , Contagem de Colônia Microbiana , Humanos , Lipopeptídeos , Masculino , Testes de Sensibilidade Microbiana , Fatores de Tempo
3.
J Med Microbiol ; 63(Pt 2): 186-194, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24184471

RESUMO

Killing rates (K) of 1-32 µg ml(-1) caspofungin were determined in RPMI-1640 and in 50 % serum using time-kill methodology against three Candida krusei (MICs of all three isolates 0.25 µg ml(-1) in RPMI-1640 and 2 µg ml(-1) in serum) and three Candida inconspicua clinical isolates (MIC ranges 0.06-0.12 µg ml(-1) in RPMI-1640 and 0.25-0.5 µg ml(-1) in serum), against C. krusei ATCC 6258 and against one C. krusei isolate that was resistant to echinocandins (MIC 8 µg ml(-1) in RPMI-1640 and 32 µg ml(-1) in serum). In RPMI-1640, the highest mean K values were observed at 4 (-1.05 h(-1)) and 16 (-0.27 h(-1)) µg ml(-1) caspofungin for C. krusei and C. inconspicua clinical isolates, respectively. In 50 % serum, mean K value ranges at 1-32 and 4-32 µg ml(-1) concentrations for C. inconspicua and C. krusei were -1.12 to -1.44 and -0.42 to -0.57 h(-1), respectively. While K values against C. krusei in RPMI-1640 and 50 % serum were comparable, serum significantly increased the killing rate against C. inconspicua (P<0.0003 for all tested concentrations). In a neutropenic murine model, daily caspofungin at 1, 2, 3, 5 and 15 mg kg(-1) significantly decreased the fungal tissue burden of C. inconspicua in the kidneys (P<0.05-0.001). Against C. krusei, doses of 3, 5 and 15 mg kg(-1) caspofungin were effective (P<0.05-0.01). All effective doses were comparably efficacious for both species. Only the highest 15 mg kg(-1) caspofungin dose was effective even against the echinocandin-resistant C. krusei isolate. In 50 % serum, killing was concentration independent at effective concentrations (≥4 and ≥1 µg ml(-1) for C. krusei and C. inconspicua, respectively), suggesting that the efficacy of dose escalation is questionable. These in vitro results were also supported by the murine model.


Assuntos
Candida/efeitos dos fármacos , Candidíase/tratamento farmacológico , Equinocandinas/uso terapêutico , Animais , Candida/isolamento & purificação , Candidíase/microbiologia , Caspofungina , Modelos Animais de Doenças , Equinocandinas/farmacologia , Feminino , Humanos , Lipopeptídeos , Camundongos , Camundongos Endogâmicos BALB C , Testes de Sensibilidade Microbiana/métodos , Viabilidade Microbiana/efeitos dos fármacos , Neutropenia/complicações , Resultado do Tratamento
4.
Diagn Microbiol Infect Dis ; 73(4): 338-42, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22726529

RESUMO

Micafungin activity was determined against 24 wild-type clinical isolates and 5 American Type Culture Collection strains belonging to 8 Candida species in RPMI-1640 with and without 50% serum using broth microdilution and time-kill methodology. MIC values increased from 4- to 128-folds in 50% serum for all Candida species. Micafungin was not fungicidal against C. albicans, C. tropicalis, and against 2 of 3 C. metapsilosis at ≥0.25, 1, and 1 µg/mL, respectively, after 48 h with 50% serum, showing good fungistatic activity. Fungicidal activity at ≥2, 4, and 32 µg/mL was noticed against C. glabrata, C. inconspicua, and C. krusei isolates, respectively. Micafungin at 8-32 µg/mL showed fungistatic activity against C. parapsilosis and C. orthopsilosis. Serum decreased the in vitro activity of micafungin. With serum binding of echinocandins taken into account, safely fungistatic or fungicidal concentrations seem to require elevated doses against some Candida species, including C. parapsilosis, C. orthopsilosis, and C. krusei.


Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Meios de Cultura/química , Equinocandinas/farmacologia , Lipopeptídeos/farmacologia , Viabilidade Microbiana/efeitos dos fármacos , Soro/metabolismo , Humanos , Micafungina , Testes de Sensibilidade Microbiana , Fatores de Tempo
5.
Mycopathologia ; 174(4): 311-8, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22565489

RESUMO

Caspofungin activity was determined in vitro and in vivo against three Candida orthopsilosis, three C. metapsilosis, two C. parapsilosis sensu stricto and two C. albicans isolates. MIC values and killing activity were determined in RPMI-1640 plus 50 % human serum. Neutropenic (cyclophosphamide-treated) mice were infected intravenously. Five-day intraperitoneal treatment with caspofungin was started after 24 h postinfection. Kidney burden was analyzed using the Kruskal-Wallis test with Dunn's post-test. In killing studies, caspofungin was fungistatic and fungicidal against C. albicans at ≥0.25 and ≥2 µg/ml concentrations, respectively. Caspofungin was fungistatic at ≥8-16, ≥2-8 and at ≥2-8 µg/ml against C. parapsilosis, C. orthopsilosis and C. metapsilosis, respectively. In the murine model, C. albicans was inhibited by 1, 2 and 5 mg/kg of caspofungin (P < 0.001 compared to the controls). Against C. parapsilosis, only 5 mg/kg caspofungin was effective against both isolates (P < 0.05). Two and five mg/kg of caspofungin was effective against all C. orthopsilosis and C. metapsilosis isolates (P < 0.05 to <0.001). Serum-based killing tests proved to be useful in predicting in vivo efficacy of caspofungin against four Candida species. Caspofungin at clinically attainable concentrations proved to be effective against all four species.


Assuntos
Antifúngicos/administração & dosagem , Candida/efeitos dos fármacos , Candidíase/tratamento farmacológico , Candidíase/microbiologia , Equinocandinas/administração & dosagem , Animais , Antifúngicos/farmacologia , Candida/genética , Candida/isolamento & purificação , Caspofungina , Equinocandinas/farmacologia , Humanos , Lipopeptídeos , Masculino , Camundongos , Camundongos Endogâmicos BALB C
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...